We represented a global healthcare company in relation to an investigation conducted by DOJ and HHS-OIG into alleged violations of the False Claims Act. The alleged false claims involved the manner in which certain negative pressure wound therapy devices were being marketed and distributed as durable medical equipment. Conducted an internal investigation and negotiated a favorable settlement with DOJ, HHS-OIG, and counsel for the relator. No post-settlement oversight was required.
Resolution of FCA Case for Global Healthcare Company
Client Type: Public Company
You Also May Be Interested In:
-
Representation of Lineagen, Inc., a provider of molecular diagnostics services for individuals showing clinical presentations consistent with neurodevelopmental disorders, in its sale to Bionano Genomics, Inc. (Nasdaq: BNGO), a genome analysis company providing tools and services to scientists and clinicians conducting genetic research and patient testing, for $9.6 million
-
Served as regulatory and deal counsel to BioPlus, a leading national specialty pharmacy, and ProHealth Pharmacy Solutions, a significant provider of infusion pharmacy management services in their sale to CarepathRx a platform company formed by Nautic Partners
-
Lead counsel representing Envision, EmCare, and related entities in a qui tam lawsuit alleging that emergency department provider’s violation of licensure laws caused submission of false claims and that defendants fraudulently billed services as performed by physicians even though patients was seen only by nurse practitioners. U.S. ex rel. Taylor v. Boyko, 2019 WL 2423283 (S.D. W. Va. Jun. 6, 2019); U.S. ex rel. Taylor v. Perni, 2020 WL 2499544 (S.D. W. Va. May 14, 2020).